| First Author | Kim DH | Year | 2019 |
| Journal | Redox Biol | Volume | 24 |
| Pages | 101184 | PubMed ID | 30974318 |
| Mgi Jnum | J:291683 | Mgi Id | MGI:6443117 |
| Doi | 10.1016/j.redox.2019.101184 | Citation | Kim DH, et al. (2019) FoxO6-mediated IL-1beta induces hepatic insulin resistance and age-related inflammation via the TF/PAR2 pathway in aging and diabetic mice. Redox Biol 24:101184 |
| abstractText | FoxO has been proposed to play a role in the promotion of insulin resistance, and inflammation. FoxO is a pro-inflammatory transcription factor that is a key mediator of generation of inflammatory cytokines such as IL-1beta in the liver. However, the detailed association of FoxO6 with insulin resistance and age-related inflammation has not been fully documented. Here, we showed that FoxO6 was elevated in the livers of aging rats and obese mice that exhibited insulin resistance. In addition, virus-mediated FoxO6 activation led to insulin resistance in mice with a notable increase in PAR2 and inflammatory signaling in the liver. On the other hand, FoxO6-KO mice showed reduced PAR2 signaling with a decrease in inflammatory cytokine expression and elevated insulin signaling. Because FoxO6 is closely associated with abnormal production of IL-1beta in the liver, we focused on the FoxO6/IL-1beta/PAR2 axis to further examine mechanisms underlying FoxO6-mediated insulin resistance and inflammation in the liver. In vitro experiments showed that FoxO6 directly binds to and elevates IL-1beta expression. In turn, IL-1beta treatment elevated the protein levels of PAR2 with a significant decrease in hepatic insulin signaling, whereas PAR2-siRNA treatment abolished these effects. However, PAR2-siRNA treatment had no effect on IL-1beta expression induced by FoxO6, indicating that IL-1beta may not be downstream of PAR2. Taken together, we assume that FoxO6-mediated IL-1beta is involved in hepatic inflammation and insulin resistance via TF/PAR2 pathway in the liver. |
